JP2010507594A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010507594A5 JP2010507594A5 JP2009533598A JP2009533598A JP2010507594A5 JP 2010507594 A5 JP2010507594 A5 JP 2010507594A5 JP 2009533598 A JP2009533598 A JP 2009533598A JP 2009533598 A JP2009533598 A JP 2009533598A JP 2010507594 A5 JP2010507594 A5 JP 2010507594A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- antigen
- binding fragment
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85326006P | 2006-10-20 | 2006-10-20 | |
| PCT/US2007/082164 WO2008133706A2 (en) | 2006-10-20 | 2007-10-22 | Fully human anti-vegf antibodies and methods of using |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010507594A JP2010507594A (ja) | 2010-03-11 |
| JP2010507594A5 true JP2010507594A5 (enExample) | 2010-12-09 |
Family
ID=39926241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009533598A Pending JP2010507594A (ja) | 2006-10-20 | 2007-10-22 | 完全ヒト抗ｖｅｇｆ抗体および使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20110076279A1 (enExample) |
| EP (1) | EP2086583A4 (enExample) |
| JP (1) | JP2010507594A (enExample) |
| CN (1) | CN102006885A (enExample) |
| CA (1) | CA2666974A1 (enExample) |
| MX (1) | MX2009004027A (enExample) |
| WO (1) | WO2008133706A2 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20160082T1 (hr) | 2006-09-29 | 2016-02-26 | Oncomed Pharmaceuticals, Inc. | Sastavi i postupci za dijagnosticiranje i lijeäśenje raka |
| RU2010120674A (ru) * | 2007-10-22 | 2011-11-27 | Шеринг Корпорейшн (US) | Полностью человеческие анти-vegf-антитела и способы их применения |
| KR101093717B1 (ko) * | 2008-11-26 | 2011-12-19 | 한국생명공학연구원 | Ｖｅｇｆ―특이적인 인간항체 |
| WO2010124009A2 (en) * | 2009-04-21 | 2010-10-28 | Schering Corporation | Fully human anti-vegf antibodies and methods of using |
| US9067986B2 (en) * | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| CN102002104A (zh) * | 2009-08-28 | 2011-04-06 | 江苏先声药物研究有限公司 | 一种抗vegf的单克隆抗体及含有该抗体的药物组合物 |
| EP3485908B1 (en) | 2009-10-16 | 2021-08-18 | Mereo BioPharma 5, Inc. | Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents |
| CN102167740B (zh) * | 2010-02-25 | 2014-06-04 | 上海百迈博制药有限公司 | 一种全人源抗vegf单克隆抗体、其制备方法及用途 |
| US20120225081A1 (en) * | 2010-09-03 | 2012-09-06 | Boehringer Ingelheim International Gmbh | Vegf-binding molecules |
| US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| CN102757495A (zh) * | 2011-04-26 | 2012-10-31 | 中国人民解放军第二军医大学 | 一种全人源抗vegf抗体、其制备方法及用途 |
| CN102875676B (zh) * | 2011-07-13 | 2014-11-05 | 无锡天演生物技术有限公司 | 全人源抗人vegf单抗分子及其应用 |
| TWI583699B (zh) | 2011-09-23 | 2017-05-21 | 安可美德藥物股份有限公司 | Ｖｅｇｆ／ｄｌｌ４結合劑類及彼等之用途 |
| CA2889638A1 (en) | 2012-10-31 | 2014-05-08 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a dll4 antagonist |
| WO2014104406A1 (ja) * | 2012-12-27 | 2014-07-03 | 学校法人慶應義塾 | 骨粗鬆症治療剤及び治療剤のスクリーニング方法 |
| JP2016530244A (ja) * | 2013-12-31 | 2016-09-29 | ディベロップメント センター フォー バイオテクノロジーＤｅｖｅｌｏｐｍｅｎｔ Ｃｅｎｔｅｒ Ｆｏｒ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ | 抗ｖｅｇｆ抗体及びその使用 |
| WO2015200905A2 (en) | 2014-06-28 | 2015-12-30 | Oligasis, Llc | Dual pdgf/vegf antagonists |
| EP3212233B1 (en) | 2014-10-31 | 2020-06-24 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| US11339213B2 (en) | 2015-09-23 | 2022-05-24 | Mereo Biopharma 5, Inc. | Methods and compositions for treatment of cancer |
| US10640772B2 (en) | 2015-11-30 | 2020-05-05 | Nissan Chemical Industries, Ltd. | DNA aptamers binding to molecular targeted agents and detection method of molecular targeted medicine using the same |
| IL290457B2 (en) | 2015-12-30 | 2025-02-01 | Kodiak Sciences Inc | Antibodies and their conjugates |
| JP6949106B2 (ja) * | 2016-08-23 | 2021-10-13 | メディミューン リミテッド | 抗ｖｅｇｆ−ａ抗体ならびにそれらの使用 |
| WO2019129677A1 (en) | 2017-12-29 | 2019-07-04 | F. Hoffmann-La Roche Ag | Anti-vegf antibodies and methods of use |
| CA3092588A1 (en) | 2018-03-02 | 2019-09-06 | Kodiak Sciences Inc. | Il-6 antibodies and fusion constructs and conjugates thereof |
| WO2020127864A1 (en) * | 2018-12-21 | 2020-06-25 | F. Hoffmann-La Roche Ag | Method for improving inhibition of vegf-binding to vegf-r1 of an anti-vegf antibody |
| WO2021013064A1 (zh) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | 一种人源化vegfr2抗体及其应用 |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| WO2023109904A1 (zh) * | 2021-12-16 | 2023-06-22 | 石药集团中奇制药技术（石家庄）有限公司 | 多西他赛白蛋白组合物与vegf抑制剂或vegfr抑制剂的组合及用途 |
| KR20240164784A (ko) * | 2022-03-30 | 2024-11-20 | 시 안 오리맵 바이오테크놀로지 컴퍼니 리미티드 | 항-psma 항체, 이의 변이체 및 이의 용도 |
| CN115850470B (zh) * | 2022-12-12 | 2023-07-07 | 三门峡市眼科医院 | Vegf抗体及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69829891T2 (de) * | 1997-04-07 | 2005-10-06 | Genentech, Inc., South San Francisco | Anti-VEGF Antikörper |
| DE60131456T2 (de) * | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
| US20050232921A1 (en) * | 2001-04-13 | 2005-10-20 | Rosen Craig A | Vascular endothelial growth factor 2 |
| US7667004B2 (en) * | 2001-04-17 | 2010-02-23 | Abmaxis, Inc. | Humanized antibodies against vascular endothelial growth factor |
| US20060073141A1 (en) * | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| EP1439192A1 (en) * | 2003-01-15 | 2004-07-21 | Xerion Pharmaceuticals AG | Neuropilin-1 inhibitors |
| DK1851315T3 (en) * | 2005-02-02 | 2014-03-24 | Univ Massachusetts | HUMAN ANTIBODIES AGAINST RABIES AND APPLICATIONS THEREOF |
| RU2010120674A (ru) * | 2007-10-22 | 2011-11-27 | Шеринг Корпорейшн (US) | Полностью человеческие анти-vegf-антитела и способы их применения |
-
2007
- 2007-10-22 CA CA002666974A patent/CA2666974A1/en not_active Abandoned
- 2007-10-22 EP EP07874227A patent/EP2086583A4/en not_active Withdrawn
- 2007-10-22 CN CN2007800475418A patent/CN102006885A/zh active Pending
- 2007-10-22 WO PCT/US2007/082164 patent/WO2008133706A2/en not_active Ceased
- 2007-10-22 JP JP2009533598A patent/JP2010507594A/ja active Pending
- 2007-10-22 MX MX2009004027A patent/MX2009004027A/es unknown
- 2007-10-22 US US12/446,438 patent/US20110076279A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200241T1 (hr) | Anti-c5a vezujuće skupine s visokom blokirajućom aktivnosti | |
| JP2011207882A5 (enExample) | ||
| JP2017523786A5 (enExample) | ||
| JP2016519650A5 (enExample) | ||
| JP2009225799A5 (enExample) | ||
| JP2020504076A5 (enExample) | ||
| JP2015503909A5 (enExample) | ||
| JP2015535828A5 (enExample) | ||
| JP2017514461A5 (enExample) | ||
| JP2008529497A5 (enExample) | ||
| JP2014509510A5 (enExample) | ||
| JP2009518005A5 (enExample) | ||
| HRP20130228T1 (hr) | Antitijela s visokim afinitetom za receptor humanog il 6 | |
| JP2015504421A5 (enExample) | ||
| HRP20151019T1 (hr) | PROTUTIJELA PROTIV c-MET | |
| JP2014530215A5 (enExample) | ||
| JP2012524071A5 (enExample) | ||
| HRP20180776T1 (hr) | Antagonisti il17c za liječenje upalnih poremećaja | |
| JP2015514110A5 (enExample) | ||
| JP2013542194A5 (enExample) | ||
| JP2014500009A5 (enExample) | ||
| JP2010538608A5 (enExample) | ||
| JP2019504032A5 (enExample) | ||
| JP2014502955A5 (enExample) | ||
| JP2017500018A5 (enExample) |